Open Access

High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma

  • Authors:
    • Yushu Ruan
    • Fanjun Zeng
    • Zhiqiang Cheng
    • Xianda Zhao
    • Pin Fu
    • Honglei Chen
  • View Affiliations

  • Published online on: September 15, 2017     https://doi.org/10.3892/ol.2017.6964
  • Pages: 5727-5734
  • Copyright: © Ruan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Monocarboxylate transporter 4 (MCT‑4) serves a key function in transporting lactate across the plasma membrane in various types of human cancer. Evidence indicates that MCT‑4 expression is associated with non‑small cell lung cancer; however, the distribution and clinical significance of MCT‑4 in the lung adenocarcinoma (AC) subtype remain unknown. Thus, the aim of the present study was to explore the clinicopathological significance and prognostic values of MCT‑4 expression in lung AC. Quantum dots‑based immunofluorescence histochemistry was performed to observe the expression of MCT‑4 in 146 specimens of lung AC and corresponding normal lung tissues. MCT‑4 protein and mRNA were detected by western blotting and reverse transcription‑quantitative polymerase chain reaction from 30 fresh samples of lung AC and corresponding normal lung tissues. Of the 146 samples, 25 (17.1%) exhibited high and 121 (82.9%) exhibited low MCT‑4 expression. MCT‑4, at the protein and mRNA level, was significantly increased in tumor specimens compared with corresponding normal lung tissue (P<0.05). MCT‑4 protein expression was significantly associated with depth of invasion (P=0.034). A survival curve analysis indicated that high MCT‑4 expression in lung AC was associated with a decreased overall survival rate (P=0.001). Multivariate analysis demonstrated that high MCT‑4 level was an independent prognostic factor (hazard ratio, 3.192; 95% confidence interval, 1.804‑5.646; P=0.001) for patients with lung AC. The results have demonstrated that high MCT‑4 expression is significantly associated with the poor prognosis and disease progression of patients with lung AC. Therefore, MCT‑4 may be a candidate therapeutic target in lung AC.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ruan Y, Zeng F, Cheng Z, Zhao X, Fu P and Chen H: High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma. Oncol Lett 14: 5727-5734, 2017
APA
Ruan, Y., Zeng, F., Cheng, Z., Zhao, X., Fu, P., & Chen, H. (2017). High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma. Oncology Letters, 14, 5727-5734. https://doi.org/10.3892/ol.2017.6964
MLA
Ruan, Y., Zeng, F., Cheng, Z., Zhao, X., Fu, P., Chen, H."High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma". Oncology Letters 14.5 (2017): 5727-5734.
Chicago
Ruan, Y., Zeng, F., Cheng, Z., Zhao, X., Fu, P., Chen, H."High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma". Oncology Letters 14, no. 5 (2017): 5727-5734. https://doi.org/10.3892/ol.2017.6964